Abstract: Pharmaceutical formulations are described for use in the treatment of pulmonary arterial hypertension (PAH). The formulations comprise polymeric nanoparticles encapsulated within crosslinked polymeric hydrogel microparticles, wherein the polymeric nanoparticles carry a therapeutic agent suitable for treatment of PAH loaded within them (for example, prostacyclin synthetic analogs, PPAR ? agonists and NO donors). Preferred formulations are inhalable, dry powder pharmaceutical formulations, which are able to swell on administration to the lungs of a patient.
Type:
Grant
Filed:
January 9, 2015
Date of Patent:
April 2, 2019
Assignee:
HEART BIOTECH PHARMA LIMITED
Inventors:
Magdi Habib Yacoub, Ibrahim M El Sherbiny
Abstract: Therapeutic formulations are described for use in the treatment of chronic obstructive pulmonary disease, bronchial asthma, cystic fibrosis, chlorine inhalation, influenza and acute myocardial infarction. The formulations comprise polymeric nanoparticles or polymeric nanoparticles encapsulated within cross-linked polymeric hydrogel microparticles, wherein the polymeric nanoparticles carry a therapeutic agent suitable for treatment of chronic obstructive pulmonary disease, bronchial asthma, cystic fibrosis, chlorine inhalation, influenza, acute myocardial infarction and heart failure. Preferred formulations are inhalable, dry powder therapeutic formulations, which are able to swell on administration to the lungs of a patient.
Type:
Grant
Filed:
June 24, 2016
Date of Patent:
July 31, 2018
Assignee:
HEART BIOTECH PHARMA LIMITED
Inventors:
Magdi Habib Yacoub, Ibrahim M. El-Sherbiny